Deelo Ophthalmology
by Deelo
· Based in United States →
— AI-powered retinal imaging analysis. Advanced AI-powered ophthalmology assistant for retinal image analysis.
Freemium
Overview
Deelo Ophthalmology is an AI-powered assistant designed for retinal image analysis and comprehensive ophthalmology practice management. It is intended for ophthalmologists and optometrists in various care settings, from individual practices to larger clinics.
- What it does: The AI analyzes fundus photos and OCT scans to assist in screening for diabetic retinopathy, detecting glaucoma through cup-to-disc ratio analysis and RNFL defect detection, and assessing Age-related Macular Degeneration (AMD) by differentiating between dry and wet forms and identifying drusen, CNV, and geographic atrophy. It also supports multi-modality imaging, including OCT-A and fluorescein angiography. Beyond AI analysis, Deelo Ophthalmology offers features for managing patient records, appointment scheduling, billing, optical inventory, and surgical planning, including a cataract and IOL planner.
- How it fits a clinical or practice workflow: Deelo Ophthalmology integrates AI-powered image analysis directly into a broader practice management platform. This allows for a streamlined workflow where clinical documentation, ophthalmic imaging, scheduling, and patient billing are connected. The platform is designed to assist with complex appointment scheduling, surgical volume coordination, pre-operative testing, and post-operative care protocols.
- Notable capabilities: The tool offers automated diabetic retinopathy staging, glaucoma risk assessment, and differentiation of AMD types. It also includes glaucoma progression analysis, tracking changes in IOP, visual fields, and RNFL slopes. For surgical planning, it provides a cataract and IOL planner with power calculations and toric planning. The platform also supports refraction and contact lens management. Deelo Ophthalmology is part of a larger suite of business applications, aiming to provide an all-in-one solution for ophthalmology practices.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automated diabetic retinopathy staging with lesion detection
- Cup-to-disc ratio analysis, RNFL defect detection, and glaucoma risk assessment
- Differentiation of dry vs wet AMD, detection of drusen, CNV, and geographic atrophy
- Support for fundus photography, OCT, OCT-A, and fluorescein angiography
- Glaucoma progression analysis with IOP, visual-field, and RNFL slopes
- Cataract & IOL planner with 25-IOL catalog and power calculations
- Refraction & contact lens management
- Ophthalmic examination templates and visual acuity tracking
- Surgical planning for cataract and refractive procedures
- Optical dispensary and frame inventory management
Use Cases
- Retinal image analysis for various eye conditions
- Diabetic retinopathy screening
- Glaucoma detection and progression analysis
- AMD assessment
- Cataract and IOL planning
- Ophthalmology practice management
What Physicians Need to Know
Retinal Image Analysis (Fundus/OCT)
Deelo Ophthalmology offers advanced AI-powered retinal image analysis, supporting multi-modality input including fundus photography, OCT, OCT-A, and fluorescein angiography. It screens for diabetic retinopathy, detects glaucoma, assesses AMD, and identifies other eye conditions from these scans.
Diabetic Retinopathy Screening Accuracy
The platform provides automated diabetic retinopathy staging from none to proliferative with lesion detection. AI systems for DR screening have shown high diagnostic performance, with reported sensitivities exceeding 80% and specificities of 90% or higher. One study showed an AI system achieving 100% sensitivity for vision-threatening diabetic retinopathy and 90.5% sensitivity for referable diabetic retinopathy. Another AI system demonstrated an accuracy of 93.36% (sensitivity 95.03%; specificity 92.90%) for more-than-mild DR.
Glaucoma Detection
Deelo Ophthalmology includes features for glaucoma detection, such as cup-to-disc ratio analysis, RNFL defect detection, and glaucoma risk assessment. It also offers glaucoma progression analysis, tracking changes over time with IOP, visual-field, and RNFL slopes measured against AAO thresholds. AI algorithms have achieved high accuracy in glaucoma detection, with AROC values between 0.84 and 0.99, and some neural networks reporting 98% sensitivity and specificity.
Age-Related Macular Degeneration Screening
The tool provides AMD assessment, differentiating between dry and wet AMD, and detecting drusen, CNV, and geographic atrophy. AI can significantly speed up the imaging process for AMD evaluation and improve image contrast. Deep learning algorithms have shown high accuracy (94%) in predicting AMD progression within a year.
Autonomous vs Assistive Diagnosis
Deelo Ophthalmology functions as an advanced AI-powered ophthalmology assistant, suggesting an assistive role in diagnosis. Assistive AI models are designed to support clinicians in decision-making, providing real-time disease classification and quantification of severity. Autonomous AI systems can make clinical decisions independently, with some demonstrating performance comparable to human experts for diabetic retinopathy.
Point-of-Care Deployment
While not explicitly stated as 'point-of-care deployment' on the Deelo Ophthalmology page, the nature of AI-powered retinal imaging analysis and its integration with other business apps suggests potential for streamlined workflows in various clinical settings. AI-assisted ophthalmology is expanding eye care accessibility, especially in underserved populations. Teleophthalmology, which often utilizes such tools, allows for disease screening, diagnosis, and monitoring over any distance.
Screening Program Integration
Deelo Ophthalmology's capabilities, particularly in automated diabetic retinopathy staging and comprehensive eye analysis, make it suitable for integration into screening programs. AI-powered retinal screening is transforming how diabetic eye disease is detected and is being implemented in large-scale programs to improve early detection, streamline referrals, and optimize clinic use. Telehealth screening for DR has been found effective and can increase screening compliance.
Sensitivity & Specificity Data
For diabetic retinopathy, AI systems have demonstrated high sensitivity and specificity. One AI system achieved 100% sensitivity for vision-threatening DR and 90.5% sensitivity with 91.1% specificity for referable DR. Another study reported an AI system with 88.9% sensitivity and 98.7% specificity for referable DR. For AMD screening, a method using fundus perimetry showed 98% sensitivity and 100% specificity. For glaucoma detection, deep learning algorithms have reported AROC values between 0.84 and 0.99, with some achieving 98% sensitivity and specificity.
FDA De Novo vs 510(k) Pathway
The Deelo Ophthalmology tool is an AI-powered assistant for retinal image analysis. The FDA 510(k) pathway is for devices substantially equivalent to a legally marketed predicate device, while the De Novo pathway is for novel devices with no existing predicate and low to moderate risk. Given the 'advanced AI-powered' nature and comprehensive disease assessment, the specific FDA pathway would depend on whether Deelo's AI algorithms are considered substantially equivalent to existing cleared devices or represent a novel technology requiring a new classification. The information provided does not specify which FDA pathway Deelo Ophthalmology has pursued or obtained.
Physician Tip
Leverage Deelo Ophthalmology's multi-modality support (fundus, OCT, OCT-A, fluorescein angiography) for a comprehensive view of retinal health. Utilize the automated DR staging and glaucoma progression analysis to efficiently monitor disease and track changes over time. The AMD assessment features can aid in early detection and differentiation of dry vs. wet AMD. While the AI provides powerful assistance, always integrate its findings with your clinical judgment and patient history for optimal care. The platform's ability to integrate with other business apps can streamline your practice's workflow beyond just image analysis.
Deelo is an all-in-one platform that combines disease analysis with over 50 integrated business apps, including CRM, invoicing, and scheduling. This means that ophthalmology disease analysis data can connect directly to patient records, billing, and appointments without requiring additional integration work. The platform aims to replace multiple separate subscriptions with a single, integrated solution.
Details
| Category | Ophthalmology AI |
| Pricing |
Freemium
|
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status | Unknown AI-estimated — unknown |
| Integrations | |
| EHR | Not specified |
| Specialties | Ophthalmology, Radiology |
Ratings & Reviews
Rate Deelo Ophthalmology
Press & Coverage
Deelo (Official Website)
Ophthalmology Practice Management Software for Ophthalmology Practices - Deelo
Deelo offers ophthalmology practice software with ophthalmic examination templates, visual acuity tracking, surgical planning, and imaging integration, alongside 50+ other business apps. It aims to replace standalone solutions like EMA by Modernizing Medicine at a fraction of the cost.
2026-07
Deelo (Official Website)
Deelo vs EMA by Modernizing Medicine: Ophthalmology Practice Software Compared for 2026
This article compares Deelo's ophthalmology practice software with EMA by Modernizing Medicine, highlighting Deelo's integrated platform and cost-effectiveness. It suggests Deelo as an alternative that includes CRM, invoicing, and scheduling.
2026-07
Deelo (Official Website)
Deelo vs NextGen Healthcare: Ophthalmology Practice Software Compared for 2026
Deelo's official website features a comparison article positioning its ophthalmology practice software against NextGen Healthcare, emphasizing its comprehensive suite of business applications.
2026-07
Deelo (Official Website)
Deelo vs RevolutionEHR: Ophthalmology Practice Software Compared for 2026
An article on Deelo's website compares its ophthalmology practice solution to RevolutionEHR, promoting Deelo's integrated approach and additional business functionalities.
2026-07
Deelo (Official Website)
Best EMA by Modernizing Medicine Alternatives in 2026
Deelo presents itself as a top alternative to EMA by Modernizing Medicine, offering a broader range of business applications integrated with its ophthalmology practice software.
2026-07
Deelo (Official Website)
Best Ophthalmology Practice Management Software for Every ...
Deelo promotes its ophthalmology practice management software as a free-to-start solution that integrates all business apps in one place, including CRM and invoicing.
2026-07
Videos
Product demos, reviews, and walkthroughs for Deelo Ophthalmology.
Loading videos...
Frequently Asked Questions
Deelo Ophthalmology offers AI-powered retinal imaging analysis to screen for diabetic retinopathy, detect glaucoma, and assess Age-related Macular Degeneration (AMD) from fundus photos and OCT scans. It also includes features for glaucoma progression analysis, cataract and IOL planning, and refraction and contact lens management. Physicians can use these tools to enhance diagnostic accuracy, monitor disease progression, and streamline surgical planning and patient management workflows.
Deelo Ophthalmology supports HIPAA compliance by encrypting retinal scans, visual fields, IOP readings, and patient records at rest. This ensures that sensitive patient data is protected according to regulatory standards.
Alternatives to Deelo Ophthalmology include EMA by Modernizing Medicine, NextGen Healthcare, and RevolutionEHR for practice management, and Viz.ai for disease analysis. While some alternatives like EMA by Modernizing Medicine offer specialty-specific EHR, Deelo aims to provide an all-in-one platform with over 50 integrated business apps.
Deelo Ophthalmology is included in every Deelo plan, with a free tier available that includes all features. Paid plans start at $19 per seat per month for the 'Starter' plan, $39 per seat per month for 'Business', and $69 per seat per month for 'Enterprise', with no long-term contracts. This transparent pricing model aims to be more affordable compared to some standalone ophthalmology practice tools.
While Deelo's AI assists with screening and detection, it's important to note that AI in ophthalmology generally has limitations. AI systems may not replace a comprehensive exam, especially for conditions like glaucoma which require multimodal assessment beyond fundus imaging. Additionally, current AI algorithms often diagnose only one disease, meaning a correct AI diagnosis is not a comprehensive clinical workup, and there's a risk of error by omission. The performance of AI can also vary by population, imaging equipment, and clinical setting.
Suggest an Edit →
| Last Verified: 2026-07-26 | First Added: 2026-07-26